The pharmacokinetics of irbesartan in hypertensive children and adolescents

  • Sakarcan A
  • Tenney F
  • Wilson J
 et al. 
  • 6


    Mendeley users who have this article in their library.
  • 54


    Citations of this article.


An open-label study was conducted to characterize the pharmacokinetics and antihypertensive response to irbesartan in children (1-12 years) and adolescents (13-16 years) with hypertension. Patients received single once-daily oral doses of irbesartan 2 mg/kg (maximum of 150 mg once daily) for 2 to 4 weeks (+/- nifedipine or hydrochlorothiazide). Plasma irbesartan concentrations were determined by a validated high-performance liquid chromatography/fluorescence method from blood samples taken predose, up to 24 hours after dosing on Day 1, and up to 48 hours after the final dose. The plasma concentration-time profiles were similar between the 6- to 12-year and the 13- to 16-year age groups and to that previously determined from a study of adult subjects receiving approximately 2 mg/kg (i.e., 150 mg) oral irbesartan once daily. Mean reductions in systolic/diastolic blood pressure were 16/10 mmHg at Day 28 with irbesartan monotherapy (n = 8). Irbesartan was well tolerated and may be a treatment option for pediatric hypertensive patients.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • A. Sakarcan

  • F. Tenney

  • J. T. Wilson

  • J. J. Stewart

  • K. G. Adcock

  • T. G. Wells

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free